Carboxyl Containing Patents (Class 530/425)
-
Publication number: 20140341934Abstract: The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Inventors: Jacob van Spronsen, Geert-Jan Witkamp, Frank Hollman, Young Hae Choi, Robert Verpoorte
-
Publication number: 20120226028Abstract: Methods for selective extraction and fractionation of algal lipids and algal products are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which enable efficient separation of algal components. Among these components are neutral lipids synthesized by algae, which are extracted by the methods disclosed herein for the production of renewable fuels.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Applicant: Heliae Development, LLCInventor: Aniket Kale
-
Publication number: 20120213821Abstract: The invention concerns a novel method for extracting endotoxins from bacteria, and the use of said method for preparing compositions comprising endotoxins or derivatives thereof designed for human or animal use (scientific, medical usage).Type: ApplicationFiled: February 8, 2012Publication date: August 23, 2012Applicant: UNIVERSITE PARIS SUD XIInventor: Martine CAROFF
-
Publication number: 20120046454Abstract: Methods for selective extraction and fractionation of algal lipids and algal products are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which enable efficient separation of algal components. Among these components are neutral lipids synthesized by algae, which are extracted by the methods disclosed herein for the production of renewable fuels.Type: ApplicationFiled: October 4, 2011Publication date: February 23, 2012Applicant: Heliae Development, LLCInventor: Aniket Kale
-
Publication number: 20110196135Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.Type: ApplicationFiled: April 6, 2011Publication date: August 11, 2011Applicant: HELIAE DEVELOPMENT, LLCInventor: Aniket KALE
-
Patent number: 7751985Abstract: The present invention relates to a process for controllably producing silk particles including the steps of designing a particle size, setting parameters to create the particle size except one unknown parameter, calculating the unknown parameter using algorithm, dissolving a silk peptide in a solvent, adding a cleavage agent, and hydrolyzing the peptide to produce the particle in the desired size.Type: GrantFiled: December 14, 2006Date of Patent: July 6, 2010Assignee: The Hong Kong Polytechnic UniversityInventors: Yi Li, Lok Yuen Lo, Jun Yan Hu
-
Publication number: 20100167374Abstract: The present invention relates to a chromatographic method of separating biological material comprising, providing chromatographic media comprising inorganic oxide particles having an average diameter of about 2 microns or less and an average pore diameter of 300 ? or more; applying a solvent comprising said biological material to said media, wherein said biological material is reversibly bonded to said media; and eluting said biological material from said media with a solvent in less than about 2 minutes for biological material having a molecular weight of less than about 100,000 Daltons.Type: ApplicationFiled: February 21, 2008Publication date: July 1, 2010Inventors: Reno T. Nguyen, Scott Anderson, Ian Chappell
-
Publication number: 20090324650Abstract: A method for the production of a purified extract of natural allergens comprising the steps of a) extracting a natural source of allergens comprising allergenic proteins to form an extract, b) purifying of said extract to remove non-protein components to form a purified extract c) denaturating said purified extract to form a purified denaturated extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract and a method for the production of a purified extract of natural allergens comprising the steps of a) hydrolysing a denaturated allergen to form an allergen hydrolysate, b) purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are betweType: ApplicationFiled: June 28, 2007Publication date: December 31, 2009Inventors: Thierry Legon, Sabine Pirotton, Gael Placier, Gilles Kergoat
-
Publication number: 20080306249Abstract: Provided is a method of removing protein while not removing nucleic acids from a biological sample containing protein, the method including: adding a compound of formula I below and a protein nucleating agent to the biological sample containing protein: where at least two of R1, R2, and R3 substituents are substituted or unsubstituted C1-C6 alkyl groups and the other substituent is a hydrogen atom or a substituted or unsubstituted C1-C6 alkyl group, a is an integer of 1 to 6 and b is 0 or 1, wherein b is 0 when a is not 1; treating the resultant mixture with a hydrophobic surface material in order to obtain a protein-free mixture; and separating the protein-free mixture from the hydrophobic surface material to which the protein is bound. By using the method, the protein can be selectively, effectively removed from the biological sample containing the protein while a nucleic acid is maintained in the sample.Type: ApplicationFiled: April 22, 2008Publication date: December 11, 2008Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Myo-yong LEE, Ki-woong HAN
-
Process for Isolating Biomaterial From Tissue and an Isolated Biomaterial Extract Prepared Therefrom
Publication number: 20080188642Abstract: A process for isolating a biomaterial extract from tissue is disclosed. The process comprises the step of contacting the tissue with an extracting solution so as to extract a biomaterial into solution. A solution containing the biomaterial extract is separated before being freeze-dried at a rate sufficient to enable the biomaterial to be isolated. The examples relate to the extraction of collagen from skin or hide using an acetic acid solution as the solvent.Type: ApplicationFiled: September 9, 2004Publication date: August 7, 2008Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Jackie Y. Ying, Shona Pek -
Patent number: 6869934Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.Type: GrantFiled: July 18, 2001Date of Patent: March 22, 2005Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Hiroshi Mizokami, Shinichi Furukawa, Keishin Sugawara, Tatsufumi Onchi, Kazuhiro Komatsu, Satoshi Koyanagi, Hideo Yoshizaki
-
Method for the purification and aqueous fiber spinning of spider silks and other structural proteins
Patent number: 6620917Abstract: Methods are described for the purification and spinning of recombinant and non-recombinant proteins. Specifically, the lysis of bacteria and purification of silk proteins occur in a single solution of organic acid. Bacterial proteins are hydrolyzed while the silk protein remains intact. Silk proteins remain soluble as they are concentrated into a aqueous-based mixture for fiber spinning.Type: GrantFiled: January 20, 2000Date of Patent: September 16, 2003Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Charlene Mello, Steven Arcidiacono, Michelle M. Butler -
Patent number: 6562951Abstract: A method for the solubilization and/or naturation of a somatotropin involves contacting a somatotropin with a detergent composition and water under conditions effective to obtain a naturated somatotropin, wherein the detergent composition may be a C10, C12, C16 or C18 acyl glutamate, a C10, C14 or C18 alkyl sulfate, an alcohol ethoxy sulfate, lauroyl ethylenediamine-triacetic acid (LEDA), a C10 to C18 linear alkyl benzene sulfonate, diphenyl disulfonate or an acyl amino acid.Type: GrantFiled: November 2, 2001Date of Patent: May 13, 2003Assignee: Monsanto Technology LLCInventors: S. Bradley Storrs, Jacob S. Tou, Jessica Marie Ballinger
-
Patent number: 6410694Abstract: A method for the solubilization and/or naturation of a somatotropin involves contacting a somatotropin with a detergent composition and water under conditions effective to obtain a naturated somatotropin, wherein the detergent composition may be a C10, C12, C16 or C18 acyl glutamate, a C10, C14 or C18 alkyl sulfate, an alcohol ethoxy sulfate, lauroyl ethylenediamine-triacetic acid (LEDA), a C10 to C18 linear alkyl benzene sulfonate, diphenyl disulfonate or an acyl amino acid.Type: GrantFiled: December 15, 1999Date of Patent: June 25, 2002Assignee: Monsanto Technology LLCInventors: S. Bradley Storrs, Jacob S. Tou, Jessica Marie Ballinger
-
Patent number: 6335430Abstract: The invention relates to a process of producing MAP-products from mussel feet. The process is characterised by extracting the mussel feet in a weakly acid aqueous solution containing, for instance, 1-10 percent by weight of a weak acid and 0.5-3 percent by weight of perchloric acid, whereafter the proteins in the aqueous solution are precipitated by adding inorganic or organic salts and separated from the system, subsequent to having extracted the solid substances.Type: GrantFiled: November 28, 2000Date of Patent: January 1, 2002Inventor: Magnus Qvist
-
Patent number: 6326029Abstract: A resorbable extracellular matrix for reconstruction of cartilage tissue, the matrix being substantially free from non-native collagen, and including a purified collagen II material formed form natural cartilage and having fibers of native collagen II which are physiologically acceptable for implant into a mammalian body.Type: GrantFiled: November 10, 1997Date of Patent: December 4, 2001Assignee: Ed Geistlich Soehne AG fuer Chemische IndustrieInventors: Peter Geistlich, Myron Spector, Zdenek Eckmayer
-
Patent number: 6043216Abstract: An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surface. Novel amino acid sequences are shown for the amino-acid terminus and 6 interval fragments. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.Type: GrantFiled: April 10, 1997Date of Patent: March 28, 2000Assignee: Arch Development CorporationInventors: F. Gary Toback, John C. Lieske
-
Patent number: 6034224Abstract: A method for the solubilization and/or naturation of a somatotropin involves contacting a somatotropin with a detergent composition and water under conditions effective to obtain a naturated somatotropin, wherein the detergent composition may be a C.sub.10, C.sub.12, C.sub.16 or C.sub.18 acyl glutamate, a C.sub.10, C.sub.14 or C.sub.18 alkyl sulfate, an alcohol ethoxy sulfate, lauroyl ethylenediamine-triacetic acid (LEDA), a C.sub.10 to C.sub.18 linear alkyl benzene sulfonate, diphenyl disulfonate or an acyl amino acid.Type: GrantFiled: December 31, 1997Date of Patent: March 7, 2000Assignee: Monsanto CompanyInventors: S. Bradley Storrs, Jacob S. Tou, Jessica Marie Ballinger
-
Patent number: 5998589Abstract: The invention is a method of purifying Factor VIII comprising the steps of contacting a solution containing Factor VIII with a Factor VIII-binding substrate under conditions sufficient to bind Factor VIII to the substrate, wherein the Factor VIII-binding substrate comprises one or more peptides bound to the substrate, wherein the peptides are selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and then eluting the bound Factor VIII.Type: GrantFiled: July 9, 1999Date of Patent: December 7, 1999Assignee: Bayer CorporationInventors: Joseph A. Buettner, June P. Davis
-
Patent number: 5886157Abstract: The invention provides a nucleic acid encoding a human cytochrome P450 2E1 comprising a 5' terminal deletion of 63 nucleotides, thereby encoding methionine at the first codon position of the 5' terminus, the codon ATG in the second codon position of the 5' terminus, and silent adenine and thymine nucleotide substitutions in the 5' region. The invention also provides a nucleic acid encoding a human cytochrome P450 2C10 comprising a 5' terminal deletion of nucleotides 7 through 60, thereby encoding methionine at the first codon position and alanine at the second position of the 5' terminus, and silent adenine and thymine nucleotide substitutions in the 5' region. The present invention also provides a method of purifying a recombinant cytochrome P450 protein from a host cell culture comprising the steps of: a. fractionating the host cells to prepare their membranes; b. adding a non-ionic detergent in a concentration of between 0.Type: GrantFiled: February 10, 1994Date of Patent: March 23, 1999Assignee: Vanderbilt UniversityInventors: F. Peter Guengerich, Zuyu Guo, Punam Sandhu, Elizabeth M. J. Gillam
-
Patent number: 5840849Abstract: Blends of collagen type I and collagen type III having crosslinks of the pyridinoline (Pyrid), dihydroxylysinonorleucine (DHLNL) and histidinohyroxylysinonorleucine (HHL) types, wherein the amounts of the crosslinks satisfy the ratio: (Pyrid+DHLNL)/HHL=0.4-6. Collagen blends with these crosslinking ratios make excellent casings with improved properties for food products, particularly sausages.Type: GrantFiled: July 29, 1997Date of Patent: November 24, 1998Assignee: Loders Croklaan B.V.Inventors: A J Bailey, Michael de Mari, Bettina Schmidl, Fransiscus Aloysius Timmermans
-
Patent number: 5610284Abstract: There are disclosed (i) a purification process for obtaining a human BCDF having the intramolecular disulfide linkage and the stereostructure of natural type human BCDF which comprises subjecting to an oxidation reaction and a refolding treatment a reduced type human BCDF obtained by culturing a microorganism having a human BCDF gene integrated therein and solubilized with guanidine hydrochloride, characterized in that after the oxidation reaction, a gel filtration chromatographic treatment is conducted under the conditions of the guanidine hydrochloride concentration adjusted to 4-7M; (ii) a purification process for obtaining a natural type human BCDF monomer by removing the organic solvent from an organic solvent-containing solution of human BCDF, characterized in that the solution is passed through a gel filtration chromatographic column equilibrated with an organic solvent, followed by eluting according to a stepwise or linear gradient program; and (iii) a human BCDF purification process comprising an ionType: GrantFiled: July 15, 1994Date of Patent: March 11, 1997Assignee: Ajinomoto Co., Inc.Inventors: Daisuke Ejima, Yutaka Sato, Mayumi Watanabe, Masayo Date, Yoshiyuki Takahara
-
Patent number: 5367054Abstract: The present invention relates to methods for the isolation and purification of immunoglobulins or fragments thereof or other biologically active factors from non-immune or immune egg yolk, by extracting the yolk with a composition containing one or more medium-chain fatty acids. The present methods provide egg immunoglobulin of high purity and high yield.Type: GrantFiled: April 12, 1993Date of Patent: November 22, 1994Assignee: Stolle Research & Development Corp.Inventor: Young-Zoon Lee
-
Patent number: 5324823Abstract: The invention provides a selective adsorbent for cellular fibronectin (cFN) and a method for fractional purification of FN which includes contacting an FN material containing plasma fibronectin (pFN) and cFN with a crosslinked polysaccharide sulfate and/or an immobilized polysaccharide sulfate to fractionate the pFN and cFN.By the fractional purification method of the invention, cFN and pFN can be fractionated in an expedient manner and with high efficiency and both pFN and cFN can be recovered in high purity and good yield.Type: GrantFiled: November 19, 1992Date of Patent: June 28, 1994Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Kaneji Asakawa, Ryoichi Umemoto, Kazuo Hino, Eiji Sakashita, Takashi Komai
-
Patent number: 5258497Abstract: The present invention relates to processes for purifying annexines. The overall process includes the steps of preparing a homogenized cell preparation and adjusting the pH to about 8.0 to 10.0, adding at least one bivalent cation, adding a phospholipid, washing the insoluble cell residue to remove the soluble constituents, and extracting the annexines from the cell residue with a chelating agent. This process initially promotes the adsorption of the annexines onto the insoluble cell residue or membrane of the host organism. The adsorption step makes it possible to eliminate unwanted soluble matter from the homogenized material by simple washing. Desorption is accomplished by using a chelating agent.Type: GrantFiled: July 13, 1990Date of Patent: November 2, 1993Assignee: Boehringer Ingelheim International GmbHInventors: Christiaan Reutelingsperger, Gerhard Bodo
-
Patent number: 5245012Abstract: A recombinant spider silk protein can be obtained in a commercially useful form by cloning and the expression in a host cell of a polynucleotide encoding an endogenous spider silk protein or variant thereof. The sequencing of a spider silk protein is made possible by a method for solubilizing a spider silk protein.Type: GrantFiled: September 29, 1992Date of Patent: September 14, 1993Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Stephen J. Lombari, David L. Kaplan
-
Patent number: 5071958Abstract: A composition for use in inducing binding between parts of mineralized tissue by regeneration of mineralized tissue on at least one of the parts, containing as an active constituent a protein fraction originating from a precursor to dental enamel, so called enamel matrix;a process for inducing binding between parts of living mineralized tissue by regeneration of mineralized tissue on at least one of the parts using such composition.Type: GrantFiled: September 12, 1990Date of Patent: December 10, 1991Assignee: Bioventures N.V.Inventors: Lars Hammarstrom, Leif Blomlof, Sven Lindskog
-
Patent number: 4894444Abstract: Immunologically intact protein or peptide immunogens are recovered from vaccines consisting of immunogen-aluminum hydroxide (alum) complexes. Recovery consists of dissolution of the complexes with an alkali metal salt of a carboxylic acid at a basic pH, reduction of the pH to physiological levels, removal of excess dissolvent and isolation of the protein or peptide immunogen.Type: GrantFiled: July 16, 1987Date of Patent: January 16, 1990Assignee: Merck & Co., Inc.Inventors: Edgar M. Scattergood, Roy W. Grabner
-
Patent number: 4873317Abstract: A method for the separation or purification of biopolymers comprises adsorbing the biopolymer on the surface of liquid oil droplets; and separating the adsorbed biopolymer from the oil droplets. The adsorbed biopolymer is separated from the oil droplets by mixing the droplets in an aqueous liquid, removing the lower aqueous phase and adding a fresh aqueous phase to the droplets, cooling the mixture to solidify and coalesce the oil and to cause it to release the adsorbed biopolymer to the fresh liquid, separating the fresh liquid and the biopolymer from the coalesced oil, separating the biopolymer from the fresh liquid.Type: GrantFiled: March 5, 1987Date of Patent: October 10, 1989Inventors: Melvyn Rosenberg, Ilana Eli
-
Patent number: 4743583Abstract: Lewis acid-Lewis base high molecular weight salt microparticulate material of the type referred to in U.S. Pat. No. 3,959,457, which include biologically active peptides and proteins solubilized in a non-aqueous, non-denaturing manufacturing solvent.Type: GrantFiled: July 20, 1987Date of Patent: May 10, 1988Assignee: Temple UniversityInventors: Tully J. Speaker, Tycho J. Speaker
-
Patent number: 4647455Abstract: Diuretic and natriuretic extracts, at least partially characterized as peptides, have been obtained by homogenization of mammalian heart atria with an aqueous solution of a lower carboxylic acid. After precipitation of impurities by pH adjustment, the extract may be further purified chromatographically. Extracts injected into text rats resulted in 30-40 fold increases in sodium and chloride excretions within 5-10 minutes of injection. Urine volume rose 10-15 fold and potassium excretion doubled. The response was complete in 20 minutes and no similar changes in renal function were observed following injection of a similarly obtained ventricular extract.Type: GrantFiled: December 18, 1984Date of Patent: March 3, 1987Assignee: Queen's University at KingstonInventor: Adolfo J. De Bold
-
Patent number: H989Abstract: A method of purifying hydrolyzed protein compositions by contact with a substantially phase-incompatible fluid extractant is provided. A reduction in the concentration of chlorohydrins, measured as 3-monochloro-1,2-propanediol, in hydrolyzed protein compositions can be obrtained by contacting the hydrolyzed protein composition with such a phase-incompatible fluid extractant, e.g., ethyl acetate. The method allows removal of chlorohydrins without substantially affecting the organoleptic qualities of the hydrolyzed protein.Type: GrantFiled: July 13, 1990Date of Patent: November 5, 1991Assignee: A. E. Staley Manufacturing Co.Inventor: Guy J. Hartman